Monovisc Drug Interactions
Currently displaying 25 drugs known to have a moderate interaction with Monovisc (hyaluronan).
- 25 moderate drug interactions
Moderate interactions with Monovisc (hyaluronan)
Note: Showing generic names only.
- benzalkonium chloride topical
- cetylpyridinium topical
- sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 (6m-5y bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 vaccine
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 311)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 312)
- sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine
- sars-cov-2 (covid-19)mrna-1273(6y+ bivalent booster) vaccine
- sars-cov-2 mrna (tozinameran 5y-11y) vaccine
- sars-cov-2 mrna (tozinameran 6m-4y) vaccine
- sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
- sars-cov-2 mrna (tozinameran) vaccine
- sars-cov-2 mrna-1273 (6m-5y) vaccine
- sars-cov-2 mrna-1273 (6y-11y) vaccine
- sars-cov-2 mrna-1273 (booster only) vaccine
- sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine
Monovisc disease interactions
There is 1 disease interaction with Monovisc (hyaluronan) which include:
More about Monovisc (hyaluronan)
- Monovisc consumer information
- Check interactions
- Compare alternatives
- Reviews (64)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: viscosupplementation agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.